MDWD - MediWound Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.0300
+0.0500 (+1.68%)
As of 1:57PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.9800
Open3.0300
Bid3.0000 x 800
Ask3.0700 x 800
Day's Range3.0000 - 3.0400
52 Week Range2.5480 - 6.1900
Volume22,306
Avg. Volume53,348
Market Cap82.352M
Beta (3Y Monthly)0.91
PE Ratio (TTM)5.08
EPS (TTM)0.5970
Earnings DateJul 28, 2017 - Jul 31, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.70
Trade prices are not sourced from all markets
  • GlobeNewswire

    Vericel and MediWound Announce Initiation of U.S. NexoBrid Expanded Access Treatment Protocol

    Vericel Corporation (VCEL) and MediWound Ltd. (MDWD) today announced initiation of the NexoBrid® expanded access treatment protocol (NEXT) to treat burn patients with deep partial- and full-thickness burns in the U.S. during the preparation and review of the NexoBrid Biologics License Application (BLA). “We are excited to initiate NEXT in the U.S. in tandem with preparations with Vericel for the BLA filing,” said Sharon Malka, MediWound’s Chief Executive Officer.

  • GlobeNewswire

    NexoBrid® Highlighted in 39 Presentations at the 18th European Burns Association Congress in Helsinki

    “We are very pleased to see NexoBrid highlighted in a meaningful number of presentations at this year’s EBA Congress,” said Sharon Malka, MediWound’s Chief Executive Officer. “This premier burn conference draws burn care specialists from around the world, and it is the ideal setting for us to showcase NexoBrid’s benefits as we continue to focus on moving forward towards U.S. commercialization with our partner, Vericel, while leveraging the strength of the clinical data generated in the EU.

  • Thomson Reuters StreetEvents

    Edited Transcript of MDWD earnings conference call or presentation 13-Aug-19 12:30pm GMT

    Q2 2019 Mediwound Ltd Earnings Call

  • Could MediWound Ltd.'s (NASDAQ:MDWD) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could MediWound Ltd.'s (NASDAQ:MDWD) Investor Composition Influence The Stock Price?

    The big shareholder groups in MediWound Ltd. (NASDAQ:MDWD) have power over the company. Institutions will often hold...

  • MediWound (MDWD) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    MediWound (MDWD) Reports Q2 Loss, Tops Revenue Estimates

    MediWound (MDWD) delivered earnings and revenue surprises of 20.00% and 194.98%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    MediWound Reports Second Quarter 2019 Financial Results

    Total revenues of $20.7 million, driven primarily by the upfront payment from Vericel for NexoBrid® license agreement BARDA committed additional $21 million to fund NexoBrid®.

  • ACCESSWIRE

    MediWound Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 13, 2019 / MediWound Ltd. (NASDAQ: MDWD ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 13, 2019 at 8:30 AM Eastern ...

  • GlobeNewswire

    MediWound to Report Second Quarter 2019 Financial Results and Host a Conference Call and Webcast on August 13

    YAVNE, Israel, Aug. 06, 2019 -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn.

  • Will MediWound (MDWD) Report Negative Q2 Earnings? What You Should Know
    Zacks

    Will MediWound (MDWD) Report Negative Q2 Earnings? What You Should Know

    MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    MediWound Launches EscharEx® U.S. Clinical Development Program

    MediWound Ltd. (the “Company”) (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced its U.S. clinical development plan for EscharEx, the Company’s topical biological drug candidate for the debridement of chronic and hard-to-heal wounds. MediWound plans to initiate an adaptive comprehensive adequately controlled Phase 2 study in the fourth quarter of 2019 for second generation EscharEx.

  • GlobeNewswire

    MediWound to Host Analyst Day on its Innovative Product EscharEx® for Debridement of Chronic Wounds

    MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, will host an analyst day on its innovative product for chronic wounds on Monday, July 22nd at 12:00pm EDT in New York City. The meeting will feature a presentation by key opinion leader (KOL) John Lantis, MD, Mount Sinai West, St. Luke’s Roosevelt Hospitals, and the Icahn School of Medicine, who will discuss the current treatment landscape as well as the unmet medical need for treating patients with chronic wounds.

  • Does The MediWound Ltd. (NASDAQ:MDWD) Share Price Tend To Follow The Market?
    Simply Wall St.

    Does The MediWound Ltd. (NASDAQ:MDWD) Share Price Tend To Follow The Market?

    Anyone researching MediWound Ltd. (NASDAQ:MDWD) might want to consider the historical volatility of the share price...

  • How Does MediWound Ltd. (NASDAQ:MDWD) Affect Your Portfolio Volatility?
    Simply Wall St.

    How Does MediWound Ltd. (NASDAQ:MDWD) Affect Your Portfolio Volatility?

    If you own shares in MediWound Ltd. (NASDAQ:MDWD) then it's worth thinking about how it contributes to the volatility...

  • Thomson Reuters StreetEvents

    Edited Transcript of MDWD earnings conference call or presentation 21-May-19 12:30pm GMT

    Q1 2019 Mediwound Ltd Earnings Call

  • GlobeNewswire

    MediWound Appoints Mr. Boaz Gur-Lavie as Chief Financial Officer

    MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the appointment of Mr. Boaz Gur-Lavie as Chief Financial Officer, effective June 11, 2019. “We are pleased to have Boaz, a skilled and experienced financial management executive, join our dedicated and experienced leadership team,” said Sharon Malka, Chief Executive Officer of MediWound.

  • GlobeNewswire

    NexoBrid® Receives Marketing Authorization from Peru’s Ministry of Health

    MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced receipt of authorization from the Ministry of Health in Peru to market and distribute NexoBrid for the removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns.  Avalon Pharmaceutical Peru S.A.C, MediWound’s exclusive distribution partner in Peru, received the marketing authorization and intends to launch NexoBrid in Peru in the first half of 2020.

  • GlobeNewswire

    BARDA Upsizes Support for NexoBrid with an Additional $21 Million to Fund Continuous Access Treatment Protocol for Thermal Burn

    MediWound to initiate NexoBrid expanded access treatment protocol (NEXT) in the third quarter of 2019, allowing for ongoing use of NexoBrid to treat burn patients in U.S. YAVNE, Israel, May 29, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has upsized its awarded contract with MediWound and provided supplemental funding of $21 million to initiate NexoBrid expanded access treatment protocol (NEXT). Under the modified contract including this supplemental amount, BARDA will provide technical assistance and a total amount of $77 million in funding for NexoBrid development activities towards U.S. marketing approval from the Food and Drug Administration (FDA).

  • MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
    Zacks

    MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

    MediWound (MDWD) delivered earnings and revenue surprises of -7.14% and -23.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press

    MediWound: 1Q Earnings Snapshot

    The Yavne, Israel-based company said it had a loss of 15 cents per share. The developer of treatments for burns and hard-to-heal wounds posted revenue of $461,000 in the period. The company's shares closed ...

  • GlobeNewswire

    MediWound Reports First Quarter 2019 Financial Results

    Met Primary and All Secondary Endpoints in Pivotal Phase 3 DETECT Study; NexoBrid BLA Filing Planned for Fourth Quarter of 2019 Signed Exclusive License Agreement with Vericel.

  • GlobeNewswire

    MediWound to Host First Quarter Financial Results Conference Call on May 21at 8:30 a.m. Eastern Time

    MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the first quarter ended March 31, 2019 at 8:30 am Eastern Time on Tuesday, May 21, 2019. Following the release, MediWound's management will host a conference call for the investment community beginning at 8:30 a.m. Eastern Time to discuss the financial results and to answer questions.

  • Vericel (VCEL) Q1 2019 Earnings Call Transcript
    Motley Fool

    Vericel (VCEL) Q1 2019 Earnings Call Transcript

    VCEL earnings call for the period ending March 31, 2019.

  • GlobeNewswire

    MediWound Enters into Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid® in North America

    MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it has entered into exclusive license and supply agreements with Vericel Corporation (VCEL) to commercialize NexoBrid® in North America (NA). NexoBrid is a topically-administered biologic product that removes eschar in patients with deep partial and full-thickness thermal burns, which is approved in the European Union and other international markets. The pivotal U.S. phase 3 DETECT clinical study met its primary and all secondary endpoints, and the submission of the Biological License Application (BLA) to the U.S. Food and Drug Administration (FDA) is planned for the fourth quarter of 2019.

  • Will MediWound (MDWD) Report Negative Q1 Earnings? What You Should Know
    Zacks

    Will MediWound (MDWD) Report Negative Q1 Earnings? What You Should Know

    MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Thomson Reuters StreetEvents

    Edited Transcript of MDWD earnings conference call or presentation 25-Mar-19 12:30pm GMT

    Q4 2018 Mediwound Ltd Earnings Call